Copenhagen, October 2022 Brain+ has successfully completed the exercise window of their IPO warrants of TO1, with a subscription percentage of 82%, which is equivalent to DKK 6,4 million. The Company will thus receive DKK 6,4 million in capital before issuing costs. The Company is pleased with the exercise, which took place at DKK 1,638…
Copenhagen, H1 2022 Gemstone is acting as the exclusive financial advisor to a prominent Danish life science company and has been the bookrunner on the two-part raise of DKK 10,4 million. Gemstone continues to work with the Company, as the management is considering the option of an IPO at the beginning of 2023.BACK
Lund, May 2022 Spermosens has successfully completed the exercise window of their IPO warrants of series TO 1, with a subscription percentage of 31%, totaling SEK 19,7 million in fresh capital to the Company. The Company is pleased with the exercise, which took place at SEK 12,29 per share, more than double the price of…
December 2021: 4.6mDKK Pre-IPO funding for life-science company DK life-science company [name undisclosed] with unique platform technology closes a pre-IPO round, as a last step prior to an anticipated IPO in 2022. Gemstone acts as the Company’s financial advisor, and facilitated the process and transaction. June 2021: 10.2mDKK pre-IPO convertible loan for Brain+ Brain+ closes…
Copenhagen, December 2021 “Best Danish share, if we look at all shares in Denmark (and not just C25) is Freetrailer with a return of as much as 354% (!)” Freetrailer was Gemstone Capital’s IPO #5 (2018) Read more about the win here (in Danish).
Copenhagen, December 2021 Brain+ lands partnership with Roche for entry in Germany 2 years ahead of plan. “Brain+ has signed a partnership agreement with RoX Health (https://roxhealth.com/), a subsidiary of the global pharma company Roche in Germany, to bring its first dementia products to the German market.” Read more about the partnership HERE. Brain+…
Copenhagen, December 2021 “ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule.” Read more about the exciting news HERE. Expres2ion was Gemstone Capital’s first IPO…
Copenhagen, December 2021 “ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. ” Read more about the exciting news HERE. Expres2ion was Gemstone Capital’s first IPO (2016)
Copenhagen, December 2021 “We are thrilled to be working together with world leading research organizations like Fraunhofer FEP and imec. Their expertise in this area is highly renown, and the fact that they are committed and enthusiastic about our project makes me very confident that we will achieve our goal,” says Clas Dyrholm, CEO of…
Copenhagen, December 2021 The total subscription in the IPO was DKK 25.4 million from a total of 1,288 subscribers, translating into a subscription percentage of 169% counting all shares offered in the offering. Read more HERE. Brain+ was Gemstone Capital’s IPO company #12 (2021)